Loading
In 69 people with locally advanced pancreatic cancer, an ordinary Smad4 stain on the diagnostic needle sample predicted whether the cancer would grow locally or spread, the finding that supports using it to decide who gets radiotherapy.
Treatment-naive patients with locally advanced pancreatic cancer (n = 69) received gemcitabine and oxaliplatin every two weeks for four doses then radiation (50.4 Gy) with concurrent capecitabine, with cetuximab throughout. Diagnostic cytology specimens were immunostained for Smad4(Dpc4). Median overall survival was 19.2 months with 1-, 2- and 4-year survival of 66.0%, 25.0% and 11.3%; radiographic local progression was 22.8% at one year and 61.0% at two. Smad4(Dpc4) expression correlated with a local rather than distant dominant pattern of disease progression (P = .016); prospective validation of Smad4 in cytology as a predictive biomarker was recommended.
It carried Iacobuzio-Donahue's autopsy finding into the clinic on a routine stain of the diagnostic sample, the basis for the still-unvalidated idea of choosing radiotherapy by SMAD4 status.
Shares SMAD4, Immunohistochemistry (IHC), Locally advanced unresectable pancreatic ductal adenocarcinoma, Journal of Clinical Oncology.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Capecitabine, Gemcitabine, Pancreatic ductal adenocarcinoma.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Gemcitabine, Pancreatic ductal adenocarcinoma.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Gemcitabine, Pancreatic ductal adenocarcinoma.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Gemcitabine, Pancreatic ductal adenocarcinoma.
Shares Capecitabine, Gemcitabine, Pancreatic ductal adenocarcinoma.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Capecitabine, Gemcitabine, Pancreatic ductal adenocarcinoma.
Shares Capecitabine, Gemcitabine, Pancreatic ductal adenocarcinoma.